U.S. pharma big copyright scrapped two experimental weight loss pills past calendar year—a when-each day tablet, lotiglipron, resulting from elevated liver enzymes along with a twice-everyday capsule, danuglipron, as a consequence of strong Unintended effects—but CEO Albert Bourla has reported the company is set to “Perform and gain” while